特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
563401

世界の呼吸器疾患治療薬市場:2023年

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

出版日: | 発行: GlobalData | ページ情報: 英文 155 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
世界の呼吸器疾患治療薬市場:2023年
出版日: 2017年09月01日
発行: GlobalData
ページ情報: 英文 155 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界における呼吸器疾患治療薬市場の収益は、2016年の309億米ドルから2023年には413億米ドルへ、4.23%のCAGR (年間複合成長率) で拡大すると予測されています。

当レポートでは、世界の呼吸器疾患治療薬市場について調査分析し、上市製品、パイプライン製品、市場予測、企業分析、戦略的統合など、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 上市製品

  • 概要
  • Advair - GSK
  • Symbicort - AstraZeneca/Astellas
  • Spiriva - Boehringer Ingelheim
  • Xolair - Roche/Novartis
  • Ventolin - GSK
  • Pulmicort - Astra Zeneca
  • Orkambi - Vertex
  • Relvar/Breo Ellipta - GSK
  • Singulair - Merck & Co.
  • Esbriet - Roche
  • Kalydeco - Vertex
  • 結論

第4章 パイプライン情勢の評価

  • 概要
  • パイプライン開発情勢
  • パイプラインにおける分子標的
  • 治験
    • 開発段階、適応症、分子タイプ、および分子標的別による失敗率
    • 開発段階、適応症、分子タイプ、および分子標的別による治験期間
    • 開発段階、適応症、分子タイプ、および分子標的別による治験規模
    • 開発段階、適応症、分子タイプ、および分子標的別による総臨床プログラム規模
  • 主なパイプライン製品の評価
    • Ivacaftor および Tezacaftor - Vertex
    • (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva
    • Dupixent - Regeneron Pharmaceuticals/Sanofi
    • Benralizumab - AstraZeneca/Medimmune
    • Tralokinumab - AstraZeneca
    • PT010(Budesonide plus Formoterol Fumarate plus Glycopyrrolate) - AstraZeneca/Pearl Therapeutics
    • 結論
  • 結論

第5章 複数シナリオの予測

  • 全体的な市場規模
  • ジェネリック医薬品の普及
  • 収益予測:分子標的別
    • Gタンパク質共役受容体 (GPCR)
    • 免疫/炎症メディエーター
    • 転写因子
    • 信号伝達
    • CFTRモジュレーター

第6章 企業分析・ポジショニング

  • 収益・市場シェア分析:企業別
    • GlaxoSmithKline
    • Vertex
    • AstraZeneca
    • Roche
    • Boehringer Ingelheim
    • Novartis
    • Teva
    • Sumitomo Dainippon
    • Regeneron
    • Merck & Co.
  • 企業情勢
  • 上市薬・パイプライン薬のポートフォリオ分析

第7章 戦略的統合

  • ライセンス取引
  • 共同開発取引

第8章 付録

図表

目次
Product Code: GBIHC453MR

Executive Summary:

Respiratory disorders, which affect components of the respiratory system such as the lungs and airway, are a broad range of chronic diseases with a variety of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate the muscles surrounding the bronchial tubes to relax and open the airways.

Recently approved products in COPD include multiple LABA/LAMA fixed-dose combinations, some of which are forecast to generate over $1 billion by 2023, and include GlaxoSmithKline (GSK)'s triple-combination therapy (fluticasone furoate plus umeclidinium bromide plus vilanterol trifenatate). The approval of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab), marketed by GSK, is also forecast to have a strong commercial impact on the market. Notable drivers of growth in the cystic fibrosis (CF) market are the recently approved disease-modifying therapies Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), both from Vertex.

Respiratory therapy area consists of indications that affect the lungs, bronchi, trachea, larynx, pharynx and nose in different ways, such as the scarring of lung tissue or the excessive production of mucus. Respiratory disease most commonly results in breathing difficulties, which can lead to disruptions in sleep, wheezing, anxiety and stress. In more severe cases shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders varies significantly across each indication and includes factors such as environment, occupation, genetic predisposition and aging.

In 2016, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 30.3% of the market, while Vertex had a small market share of 5.3%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease-modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Orkambi and Kalydeco, both of which were developed by Vertex.

The report "Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers" provides the following analysis -

  • Provides introduction to respiratory disorders, including disease epidemiology, symptoms, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided. The chapter concludes with an analysis of the general treatment options.
  • Provides overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the respiratory disorders pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: leukemia, lymphoma and myeloma. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to respiratory disorder products. Some of the most prominent deals are discussed in detail.

Scope:

  • Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
  • The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
  • There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
  • The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
  • There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?

Reasons to buy:

  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.
  • Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Symptoms
  • 2.3. Diagnosis
    • 2.3.1. Asthma
    • 2.3.2. Chronic Obstructive Pulmonary Disease
    • 2.3.3. Idiopathic Pulmonary Fibrosis
    • 2.3.4. Cystic Fibrosis
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Asthma
    • 2.4.2. Chronic Obstructive Pulmonary Disease
    • 2.4.3. Idiopathic Pulmonary Fibrosis
    • 2.4.4. Cystic Fibrosis
  • 2.5. Epidemiology
    • 2.5.1. Asthma
    • 2.5.2. Chronic Obstructive Pulmonary Disease
    • 2.5.3. Idiopathic Pulmonary Fibrosis
    • 2.5.4. Cystic Fibrosis
  • 2.6. Prognosis and Disease Staging
    • 2.6.1. Asthma
    • 2.6.2. Chronic Obstructive Pulmonary Disease
    • 2.6.3. Idiopathic Pulmonary Fibrosis
    • 2.6.4. Cystic Fibrosis
  • 2.7. Treatment
    • 2.7.1. Asthma
    • 2.7.2. Chronic Obstructive Pulmonary Disease
    • 2.7.3. Idiopathic Pulmonary Fibrosis
    • 2.7.4. Cystic Fibrosis

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Advair - GSK
  • 3.3. Symbicort - AstraZeneca/Astellas
  • 3.4. Spiriva - Boehringer Ingelheim
  • 3.5. Xolair - Roche/Novartis
  • 3.6. Ventolin - GSK
  • 3.7. Pulmicort - Astra Zeneca
  • 3.8. Orkambi - Vertex
  • 3.9. Relvar/Breo Ellipta - GSK
  • 3.10. Singulair - Merck & Co.
  • 3.11. Esbriet - Roche
  • 3.12. Kalydeco - Vertex
  • 3.13. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
  • 4.5. Assessment of Key Pipeline Products
    • 4.5.1. Ivacaftor and Tezacaftor - Vertex
    • 4.5.2. (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva
    • 4.5.3. Dupixent - Regeneron Pharmaceuticals/Sanofi
    • 4.5.4. Benralizumab - AstraZeneca/Medimmune
    • 4.5.5. Tralokinumab - AstraZeneca
    • 4.5.6. PT010(Budesonide plus Formoterol Fumarate plus Glycopyrrolate) - AstraZeneca/Pearl Therapeutics
    • 4.5.7. Conclusion
  • 4.6. Conclusion

5. Multi-scenario Market Forecast to 2023

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. G Protein-Coupled Receptors
    • 5.3.2. Immune/Inflammatory Mediators
    • 5.3.3. Transcription Factors
    • 5.3.4. Signal Transduction
    • 5.3.5. CFTR Modulator

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. GlaxoSmithKline
    • 6.1.2. Vertex
    • 6.1.3. AstraZeneca
    • 6.1.4. Roche
    • 6.1.5. Boehringer Ingelheim
    • 6.1.6. Novartis
    • 6.1.7. Teva
    • 6.1.8. Sumitomo Dainippon
    • 6.1.9. Regeneron
    • 6.1.10. Merck & Co.
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deal by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type and Molecular Target
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. Bibliography
  • 8.2. All Pipeline Drugs by Phase
    • 8.2.1. Discovery
    • 8.2.2. Preclinical
    • 8.2.3. IND/CTA-Filed/Phase 0
    • 8.2.4. Phase I
    • 8.2.5. Phase II
    • 8.2.6. Phase III
    • 8.2.7. Pre-registration
  • 8.3. Abbreviations
  • 8.4. Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Market Size and Revenue Forecasts
    • 8.4.4. Pipeline Analysis
    • 8.4.5. Competitive Landscape
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2017
  • Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age
  • Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age
  • Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults
  • Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016
  • Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016
  • Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016
  • Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016
  • Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016
  • Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016
  • Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2017
  • Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2017
  • Table 13: Respiratory Disorders Therapeutics Market
  • Table 14: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Xolair, 2017
  • Table 15: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2017
  • Table 16: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmicort, 2017
  • Table 17: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Orkambi, 2017
  • Table 18: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Relvar/Breo Ellipta, 2017
  • Table 19: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2017
  • Table 20: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2017
  • Table 21: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2017
  • Table 22: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
  • Table 23: Respiratory Disorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2017
  • Table 24: Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2017
  • Table 25: Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2017

List of Figures

  • Figure 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Asthma, 2016-2023
  • Figure 2: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for COPD, 2016-2023
  • Figure 3: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Idiopathic Pulmonary Fibrosis, 2016-2023
  • Figure 4: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Cystic Fibrosis, 2016-2023
  • Figure 5: Respiratory Disorders Therapeutics Market, Schematic Representation of Potential Clinical Courses of IPF
  • Figure 6: Respiratory Disorders Therapeutics Market, Progression of CF
  • Figure 7: Respiratory Disorders Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2017
  • Figure 8: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Advair ($bn), 2006-2023
  • Figure 9: Respiratory Disorders Therapeutics Market, Advair Market Share Within Asthma, Global, 2006-2023
  • Figure 10: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Symbicort ($bn), 2006-2023
  • Figure 11: Respiratory Disorders Therapeutics Market, Symbicort Market Share Within Asthma, Global, 2006-2023
  • Figure 12: Respiratory Disorders Therapeutic Market, Global, Annual Revenue for Spiriva ($bn), 2006-2023
  • Figure 13: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Xolair ($m), 2006-2023
  • Figure 14: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Ventolin ($bn), 2006-2023
  • Figure 15: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Pulmicort ($bn), 2006-2023
  • Figure 16: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Orkambi ($bn), 2015-2023
  • Figure 17: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Relvar/Breo Ellipta ($bn), 2013-2023
  • Figure 18: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Singulair ($bn), 2006-2023
  • Figure 19: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Esbriet ($m), 2008-2023
  • Figure 20: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Kalydeco ($m), 2012-2023
  • Figure 21: Respiratory Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
  • Figure 22: Respiratory Disorders Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017
  • Figure 23: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Stage of Development, 2017
  • Figure 24: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecule Type, 2017
  • Figure 25: Respiratory Disorders Therapeutics Market, Global, Pipeline by Molecular Targets and Stage of Development, 2017
  • Figure 26: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecular Targets, 2017
  • Figure 27: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
  • Figure 28: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
  • Figure 29: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
  • Figure 30: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
  • Figure 31: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
  • Figure 32: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
  • Figure 33: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
  • Figure 34: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
  • Figure 35: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development, 2006-2017
  • Figure 36: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006-2017
  • Figure 37: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006-2017
  • Figure 38: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006-2017
  • Figure 39: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development, 2006-2017
  • Figure 40: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication, 2006-2017
  • Figure 41: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006-2017
  • Figure 42: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006-2017
  • Figure 43: Respiratory Disorders Therapeutics Market, Global, Revenue for Ivacaftor/Tezacaftor ($bn), 2018-2023
  • Figure 44: Respiratory Disorders Therapeutics Market, Global, Revenue for (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) ($m), 2017-2023
  • Figure 45: Respiratory Disorders Therapeutics Market, Global, Revenue for Dupixent ($m), 2017-2023
  • Figure 46: Respiratory Disorders Therapeutics Market, Global, Revenue for Benralizumab ($m), 2017-2023
  • Figure 47: Respiratory Disorders Therapeutics Market, Global, Revenue for Tralokinumab ($m), 2017-2023
  • Figure 48: Respiratory Disorders Therapeutics Market, Global, Revenue for PT010 ($m), 2017-2023
  • Figure 49: Respiratory Disorders Therapeutics Market, Global, Market Size ($bn), 2016-2023
  • Figure 50: Respiratory Disorders Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023
  • Figure 51: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Modulators ($bn), 2016-2023
  • Figure 52: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Immune/Inflammatory System Targets ($bn), 2016-2023
  • Figure 53: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Transcription Factor Therapies ($bn), 2016-2023
  • Figure 54: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction Modulators ($bn), 2016-2023
  • Figure 55: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for CFTR Modulators ($bn), 2016-2023
  • Figure 56: Respiratory Disorders Therapeutics Market, Global, Company Analysis Matrix, 2016-2023
  • Figure 57: Respiratory Disorders Therapeutics Market, Global, Cluster Graph by Growth and Market Share, 2016-2023
  • Figure 58: Respiratory Disorders Therapeutics Market, Global, Forecast Revenue by Company, 2016-2023
  • Figure 59: Respiratory Disorders Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023
  • Figure 60: Respiratory Disorders Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
  • Figure 61: Respiratory Disorders Therapeutics Market, Global, Revenue by Product Type, 2016-2023
  • Figure 62: Respiratory Disorders Therapeutics Market, Global, GlaxoSmithKline Annual Revenue Forecast ($bn), 2016-2023
  • Figure 63: Respiratory Disorders Therapeutics Market, Global, Vertex Annual Revenue Forecast ($bn), 2016-2023
  • Figure 64: Respiratory Disorders Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023
  • Figure 65: Respiratory Disorders Therapeutics Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
  • Figure 66: Respiratory Disorders Therapeutics Market, Global, Boehringer Ingelheim Annual Revenue Forecast ($bn), 2016-2023
  • Figure 67: Respiratory Disorders Therapeutics Market, Global, Novartis Annual Revenue Forecast ($m), 2016-2023
  • Figure 68: Respiratory Disorders Therapeutics Market, Global, Teva Annual Revenue Forecast ($bn), 2016-2023
  • Figure 69: Respiratory Disorders Therapeutics Market, Global, Sumitomo Dainippon Annual Revenue Forecast ($bn), 2016-2023
  • Figure 70: Respiratory Disorders Therapeutics Market, Global, Regeneron Annual Revenue Forecast ($bn), 2016-2023
  • Figure 71: Respiratory Disorders Therapeutics Market, Global, Merck & Co. Annual Revenue Forecast ($bn), 2016-2023
  • Figure 72: Respiratory Disorders Therapeutics Market, Global, Companies by Type, 2017
  • Figure 73: Respiratory Disorders Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Respiratory Specialization, 2017
  • Figure 74: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, 2016-2023
  • Figure 75: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2017
  • Figure 76: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Indication, 2006-2017
  • Figure 77: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Stage of Development, 2006-2017
  • Figure 78: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2017
  • Figure 79: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2017
  • Figure 80: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Indication, 2006-2017
  • Figure 81: Respiratory Disorders Therapeutics Market, Global, Co-development Deal Volume and Value by Stage of Development, 2006-2017
  • Figure 82: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2017
  • Figure 83: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Discovery, 2017
  • Figure 84: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Preclinical, 2017
  • Figure 85: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, IND/CTA-Filed/Phase 0, 2017
  • Figure 86: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase I, 2017
  • Figure 87: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase II, 2017
  • Figure 88: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase III, 2017
  • Figure 89: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.